An Open-label, Multicenter Phase Ib/II Study to Evaluate the Safety, Efficacy and Pharmacokinetic Characteristics of ANS014004 in Combination With EGFR-TKI in Patients With EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study tests a new combination of targeted cancer medications, including an investigational drug called ANS014004, for people with a specific type of advanced lung cancer. Researchers want to find the safest doses and see if this combination can better fight the cancer when standard treatments stop working.
You may be able to join if you are 18 or older, have advanced non-small cell lung cancer with a specific EGFR gene mutation, and your cancer has progressed after previous treatments. People with certain other gene mutations or prior treatments with similar specific drugs will not be able to join.
You will receive a combination of study medications, with the first part of the study focusing on finding the safest dose. Throughout the trial, your health will be carefully watched and your tumors will be checked regularly using imaging scans like CT scans.
This study is currently getting ready to start recruiting participants and will take place in locations such as New York, New York.
- 1Tests a new drug combination to overcome treatment resistance in lung cancer.
- 2Designed for adults with specific EGFR gene mutations in their cancer cells.
- 3Involves regular check-ups and imaging scans to monitor how well the treatment works.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.